Drug Profile

SW 0128

Alternative Names: HPV16 RNA -LPP; SW-0128

Latest Information Update: 24 Nov 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Stemirna Therapeutics
Class Antineoplastics; Cancer vaccines; Immunotherapies; RNA vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Preclinical Cancer

Most Recent Events

09 Nov 2023 Stemirna Therapeutics has patent protection for LPP (lipopolyplex) nano-delivery platform in Europe and USA (Stemirna Therapeutics pipeline, November 2023)
20 Sep 2023 Preclinical trials in Cancer in China (SC) prior to September 2023
20 Sep 2023 Immunogenicity data from preclinical studies in Cancer presented at the 7th Annual International Cancer, Immunotherapy Conference (CRI-ENCI-AACR-2023)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com